Clinical trial · Interventional
TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS
TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE RISK OF CYTOKINE RELEASE SYNDROME AND DIFFERENTIAL DIAGNOSIS WITH INFECTION
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Torque Teno Virus (TTV) prevalence in the general population is very high (\>90%) and has not been consistently confirmed to cause any disease. Kidney transplant studies seem to indicate that an elevated viremia could predict the risk of de-veloping an infectious process in the following weeks. An study of the influence of TTV as a predictive marker of infection in kidney transplant recipi-ents showed higher TTV levels, even 3 months before the infectious process, allowing the authors to postulate that the quantification of TTV could help to modulate the treatment of patients at risk. Publications of subsequent studies seem to confirm these data.In the field of hematopoietic stem cell transplantation (HSCT) few studies have analyzed the replication kinetics of TTV. There seems to be a drop in TTV plasma load after conditioning treatment, with a progressive increase in the first months post-transplant, in parallel with the number of lymphocytes. In early stages of HSCT, a relation-ship between TTV replication kinetics and the probability of developing an infection by CMV has also been described. Likewise, the possible relationship of TTV with other complications of HSCT, such as Epstein-Barr virus infection (EBV) or graft-versus-host disease (GvHD), have been reported. However, not every study conducted to date show this line of results.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Cancer | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- STUDY ARM
- description
- blood samples collection
- interventionNames
- Other: blood collection
Primary outcomes (1)
- measure
- Plasma viral load and TTV replication kinetics
- timeFrame
- d0, d1, d3, d5, d7, d10, d14, d21, d28, d60 and d90 after CAR-T Cell treatment
- description
- comparaition between before during and after CART
Secondary outcomes (3)
- measure
- Plasma viral load and CMV replication kinetics
- timeFrame
- d0, d14, d28, d60 and d90 after CAR-T Cell treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult patients (\>=18 years). 2. Patient going to be treated by CAR-T Cell therapy 3. Able to comply with the protocol. 4. Written informed consent. 5. Patient affiliated to the national "Social Security" regimen or beneficiary of this regimen Exclusion Criteria: 1. Pregnancy/breast feeding. 2. Patient considered socially or psychologically unable to comply with the treatment and the required medical follow-up.
References
Publications (1)
- DERIVEDBenzaquen A, Gimenez E, Iacoboni G, Guerreiro M, Hernani R, Albert E, Carpio C, Balaguer A, Perez A, S de la Asuncion C, Sanchez-Salinas MA, Chorao P, Pinana JL, Beas F, Montoro J, Hernandez-Boluda JC, Facal A, Ferrer B, Villalba M, Amat P, Gomez MD, Campos D, Terol MJ, Sanz J, Barba P, Navarro D, Solano C. Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy. Bone Marrow Transplant. 2024 Jan;59(1):93-100. doi: 10.1038/s41409-023-02114-0. Epub 2023 Nov 2. PMID 37919456